Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- Conditions
- Gastric CancerEsophageal CancerRCCHepatocellular CarcinomaUveal MelanomaOvarian CancerRenal Cell CarcinomaTriple-negative Breast CancerGastroesophageal Junction CancerMelanoma
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT03652077
- Locations
- 🇺🇸
The Angeles Clinical and Research Institute, Los Angeles, California, United States
🇺🇸Hackensack Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Mississippi, Jackson, Mississippi, United States
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03627052
A Study of INCB050465 in Primary Sjögren's Syndrome
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT03627065
- Locations
- 🇺🇸
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇺🇸North Georgia Rheumatology Group, Lawrenceville, Georgia, United States
🇺🇸Advanced Pharma CR, Miami, Florida, United States
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT03607487
- Locations
- 🇩🇪
Investigative Site, Lübeck, Schleswig-Holstein, Germany
🇨🇦Investigative Site 009, Markham, Ontario, Canada
🇨🇦Investigative Site 008, Richmond Hill, Ontario, Canada
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 107
- Registration Number
- NCT03599713
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 94
- Registration Number
- NCT03597295
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷Centre Hospitalier Universitaire de Besancon, Besancon, France
🇺🇸Maryland Oncology Hematology P.A., Rockville, Maryland, United States
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Conditions
- Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT03589651
- Locations
- 🇺🇸
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 155
- Registration Number
- NCT03584516
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT03569371
- Locations
- 🇺🇸
Investigative Site, Hershey, Pennsylvania, United States
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03538041
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇮🇹AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARIT� DI NOVARA, Novara, Italy